KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.96

The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial.

Matthew W Jenner, Charlotte Pawlyn, Faith E Davies, Tom Menzies, Anna Hockaday, Catherine Olivier, John R Jones, Kamaraj Karunanithi, Jindriska Lindsay, Bhuvan Kishore, Gordon Cook, Mark T Drayson, Martin F Kaiser, Roger G Owen, Walter Gregory, David A Cairns, Gareth J Morgan, Graham H Jackson, UK National Cancer Research Institute (NCRI) Haemato-oncology Clinical Studies Group

Br J Haematol 201(2) 267-279

PMID36541152
PMCIDPMC10952726
DOI10.1111/bjh.18600
发表日期2022-12-21
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

Lenalidomide is an effective maintenance agent for patients with myeloma, prolonging first remission and, in transplant eligible patients, improving overall survival (OS) compared to observation. The 'Myeloma XI' trial, for newly diagnosed patients, aimed to evaluate whether the addition of the histone deacetylase inhibitor vorinostat to the lenalidomide maintenance backbone could improve outcomes further. Patients included in this analysis were randomised to maintenance therapy with lenalidomide alone (10 mg/day on days 1-21 of each 28-day cycle), or in combination with vorinostat (300 mg/day on day 1-7 and 15-21 of each 28-day cycle) with treatment continuing until unacceptable toxicity or progressive disease. There was no significant difference in median progression-free survival between those receiving lenalidomide-vorinostat or lenalidomide alone, 34 and 40 months respectively (hazard ratio [HR] 1.18, 95% confidence interval [CI] 0.96-1.44, p = 0.109). There was also no significant difference in median OS, not estimable and 75 months respectively (HR 0.99, 95% CI 0.76-1.29, p = 0.929). Subgroup analysis demonstrated no statistically significant heterogeneity in outcomes. Combination lenalidomide-vorinostat appeared to be poorly tolerated with more dose modifications, fewer cycles of maintenance therapy delivered and higher rates of discontinuation due to toxicity than lenalidomide alone. The trial did not meet its primary end-point, there was no benefit from the addition of vorinostat to lenalidomide maintenance.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。